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Introduction: For patients with a chronic disease, the appropriate use of medication is the 
key to manage their illness. Adherence to medication is therefore important. Adherence can be 
divided into three parts: the initiation part, the execution phase, and the discontinuation part. 
Little is known about the determinants of the initiation part. For this reason, we describe the 
conduct of a stepwise procedure to study determinants of medication initiation for patients 
with a chronic disease. 
Methods/design: The stepwise procedure comprises of eliciting a list of all potential deter-
minants via literature review, interviewing patients, and consulting an expert panel. This is fol-
lowed by embedding the determinants in a theoretical framework, developing a questionnaire, 
and choosing adherence measurement methods. The consecutive steps that we conducted for 
the development of a tool for the prediction of adherence in our study sample of early arthritis 
patients are described. 
Discussion: Although we used a thorough procedure, there are still some pitfalls to take into 
account, such as the choice of theoretical framework. A strength of this study is that we use mul-
tiple adherence measurement methods and that we also take clinical outcomes into account. 
Keywords: adherence, chronic disease, methodology, arthritis, medication 
Introduction
For patients with a chronic disease who respond well to drug treatment, appropri-
ate use of medication is the key to managing their illness. However, over 30% of 
prescribed medication is not taken as directed.1 A meta-analysis from 2004 assessed 
over 50 years of research on chronic medication adherence and calculated an overall 
nonadherence rate of 24.8%.2 For rheumatoid arthritis (RA), the nonadherence rates 
range between 1.5% and 50.5%.3
Nonadherence wastes resources, and is related to preventable morbidity and mor-
tality.4 For example, in the rheumatology practice, patients with RA are treated with 
disease-modifying antirheumatic drugs (DMARDs) to induce disease remission and 
prevent disability. When not sufficiently adhering to their treatments, patients may 
present as nonresponders to the treatment, resulting in a switch to a more expensive 
treatment with biologicals. When rheumatologists get better insight into patients 
who are potentially nonadherent, unnecessary switches to other therapies might be 
prevented.5 
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To prevent nonadherence, early recognition of potential 
nonadherence behavior is necessary. This requires patient 
profiling to distinguish those at risk for nonadherence from 
adherent patients. A frequently cited definition of adher-
ence is “the extent to which a person’s behavior – taking 
medication, following a diet, executing lifestyle changes – 
follows medical advice.”6 It is a continuous process, which 
can be divided into three parts: acceptance, execution, and 
discontinuation.7 In the acceptance phase, the patient learns 
to accept the need for the medication and learns to fit the 
medication schedule into daily life.8 This phase initiates 
the execution of medication intake. For RA patients, this is 
the part where they start to experience the effect and side 
effects of the DMARDs. It takes approximately 3 months 
before the full effectiveness of the DMARDs can be felt and 
tested. Unfortunately, most studies on adherence focus on the 
execution phase and skip this important phase that precedes 
the execution phase: the initiation of medication. 
The focus of studies on the execution phase means that, 
although we do have some insight into the prevalence of 
nonadherence in the execution phase, even in that phase we 
still do not have a clear view of what causes nonadherence. 
Nonadherence is a complicated phenomenon, and decades of 
research show unequivocal relationships with both modifi-
able factors and unmodifiable factors.6,9 Frequently studied 
factors are medication characteristics, perceptions and cog-
nitions about illness and medication, socioeconomic and 
demographic factors, disease features, and the doctor-patient 
relationship.3,6 Although these factors are widely studied, the 
evidence for the association with adherence points in different 
directions.3 For example, some studies report higher age as 
a risk factor for nonadherence in RA patients, whereas other 
studies report lower age as a risk factor for nonadherence in 
RA.3 This can be due to a number of factors, such as the use of 
different adherence measurement instruments. Another prob-
lem is that most studies on medication adherence in chronic 
patients do not include a consistent behavioral model to 
explain nonadherence. A behavioral model directs research, 
indicates which factors are potentially relevant, and helps 
to gain insight into the relationship between the determinants 
that guide behavior. When a behavioral model is missing, it 
could be that relevant factors are missed. 
Moreover, research mostly focused on unmodifiable 
determinants of adherence, such as disease features or demo-
graphic characteristics. An example is the work of Curtis 
et al who showed which osteoporosis patients are at risk 
for nonadherence for bisphosphonates, but only identified 
unmodifiable risk factors.10 Although these unmodifiable 
determinants give us some clues for the target of interven-
tions, we also need to study modifiable determinants, so that 
interventions can be developed. 
We know from the scarce literature on the initiation of 
medication that a) expecting health problems from not treat-
ing the disease; b) the ability to obtain information during 
treatment; c) negative attitudes toward medication; and d) a 
relative lack of insight, are associated.11,12 We do not know 
whether the results of the studies that were conducted on 
factors influencing medication adherence in the execution 
phase are also applicable to the starting phase. 
We aim to study factors that are possibly associated to 
the initiation of medication therapy, with the final goal to 
develop a prediction instrument for the early recognition of 
patients at risk for nonadherence. In this article we describe 
the study protocol as a stepwise procedure with background 
information to examine possible determinants of medica-
tion initiation. We use the population of newly diagnosed 
inflammatory arthritis patients starting on DMARD therapy 
as an example. The aim of this paper is to describe how to 
study possible determinants of adherence by using a stepwise 
procedure. 
Methods/design
We describe which steps are needed to develop a preliminary 
set of determinants. Thereafter, we describe the study setup 
and how to develop the prediction instrument. The process 
contains the following steps: systematic literature search, 
patient perspective, expert panel, application of a theoretical 
framework, selection of questions, and selection of adherence 
measurement instrument.
Systematic literature search
The first step to gain insight into relevant and modifiable 
determinants of adherence is systematically reviewing the 
literature. A large amount of research tried to assess determi-
nants of adherence. Reviewing all the literature on this topic 
is therefore not advisable. Instead, it is useful to review the 
literature on the topic that is of interest: a particular disease 
or medication, or a particular adherence phase, such as the 
initiation or discontinuation of medication. It is important to 
remember that determinants may differ for various diseases. 
Patients with arthritis might be driven by feelings of pain to 
take their medication, whereas for hypertension, patients may 
have no symptoms, and their adherence behavior might be 
driven by adverse cardiovascular outcome. 
In this example, we wanted to gain insight into factors 
affecting adherence in recent onset (rheumatoid) arthritis 
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patients. When searching the literature, we discovered 
that there was no information on recent onset arthritis, so 
we broadened our search terms into established disease, 
because then we at least got insight into factors influencing 
adherence. The literature was systematically searched from 
inception to February 2012 to identify studies on factors 
affecting medication adherence in patients with (rheumatoid) 
arthritis. Studies were eligible if they addressed medication 
adherence in adult (rheumatoid) arthritis patients, evaluated 
factors related to adherence, used a reproducible definition 
or validated instrument to measure adherence, and provided 
a statistical measure to reflect the strength of the asso-
ciation between the determinant and adherence. Eighteen 
observational studies remained, and were assessed on their 
methodological quality. All studies were on established RA 
patients and focused on the execution phase of adherence. 
Adherence rates ranged from 49.5% to 98.5%.3 A level of 
evidence synthesis was conducted to find the strength of the 
evidence for every factor. The factor that was associated with 
adherence to biologicals was having had a prescription for 
DMARDs 6 months prior to biological treatment. The factor 
that was associated with adherence to DMARDs is the belief 
that the medication for RA is necessary to treat the illness. 
There is also some limited evidence that the communication 
between the health care provider and the patient is influencing 
medication adherence. 
Patient perspective
When searching for relevant determinants of health behavior, 
it is important to have an overview of possible determinants 
from all relevant viewpoints. The patient perspective is a very 
relevant viewpoint. To get to know this viewpoint, individual 
or group interviews with patients need to be conducted. When 
interviewing patients on possible determinants of adherence, 
it is of importance that the interviewees are representative 
of the group of patients the prediction instrument is targeted 
on. It is also advisable to keep on conducting interviews until 
saturation of the themes has been achieved. The main goal of 
the interviews has to be taken in mind when constructing an 
interview scheme. Furthermore, it is advisable to use a theo-
retical framework when analyzing the interview data.13,14
In the literature we reviewed, the viewpoint of the patient 
was not present. We also wanted to gain insight into factors 
affecting the initiation of therapy, because we did not gather 
information about these factors from the literature review. 
Therefore, we conducted a qualitative study to learn more 
about the initiation of medication from the patient perspec-
tive. This study was a combination of six focus groups and ten 
individual interviews, with a total of 33 patients. All patients 
gave informed consent for their participation and were 
aware that their data would be used for research purposes. 
The interviews were transcribed verbatim and imported into 
ATLAS.ti software. To ensure anonymity, all identifying 
information was removed from the transcripts. Responses 
that included reasons for adherence or nonadherence in the 
initiation part were extracted and coded by two coders sepa-
rately. The same was done for the execution phase. Codes 
were classified into overarching themes. Seven factors that 
influenced medication intake behavior emerged: 1) severity 
of complaints, 2) experiences with medication, 3) percep-
tions about medication, 4) information about medication, 
5) ability to adjust to the medication schedule, 6) need to 
make autonomous or shared decisions, and 7) communica-
tion with and trust in the rheumatologist.
expert panel
The factors that were extracted from the literature review 
and the interviews were presented to an expert panel that 
consisted of one rheumatologist, one pharmacist, one psy-
chologist, two specialized rheumatology nurses, and four 
researchers in the field of rheumatology. The expert panel 
ordered the factors according to theme and according to 
perceived importance. They also proposed other potentially 
relevant determinants of adherence behavior, which were 
integrated with the other factors in Table 1. 
All potentially relevant determinants identified in the 
literature, during patient interviews, and by the expert panel 
were gathered, and ordered and clustered according to a 
theoretical framework in Table 1. 
theoretical framework
Adherence to medication requires behavior changes in the 
patient and could therefore benefit from the use of a theo-
retical framework to understand what facilitates and what 
inhibits medication intake.15 
Numerous theoretical frameworks have been developed 
and tested, but how do we know which framework to use? 
Each model has its own advantages and disadvantages. 
A brief description of the social cognition models which 
are commonly used to predict health behavior can be found 
below. 
The Health Belief Model (HBM)16 has the central assump-
tion that behavior is determined by the perceived threat of 
the health problem and the evaluation of the health behavior. 
The benefits of the behavior have to be larger than the pos-
sible disadvantages. The protection motivation theory17 holds 
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that behavior aimed at protecting one’s own health is called 
an “adaptive response”, where behavior that is regarded to 
be bad for one’s health is termed a “maladaptive response”. 
Two processes are distinguished: estimating the threat, and 
estimating the opportunities to cope with the threat. The 
person estimates the threats and, based on these estimations, 
the patient makes an adaptive or maladaptive response. 
The theory of reasoned action/theory of planned behavior18 
depicts that the intention to follow a certain behavior is the 
best predictor of behavior. The intention is influenced by 
three determinants: attitude, subjective norms, and perceived 
behavioral control. The social cognitive theory19 describes 
how human behavior is directed through the expectations that 
one holds of a certain behavior. Behavior is seen as dynamic 
and the product of interactions and influences of environmen-
tal aspects, the person, and this person’s behavior. 
There are also theories that focus on stepwise behavioral 
change; these are called “stage models”. The transtheoretical 
model of change20 describes five stages of behavioral change; 
precontemplation, contemplation, preparation, action, and 
maintenance. The precaution-adoption process21 is in some 
aspects comparable to the stages-of-change concept. In this 
process, the first step in the process from precontemplation 
to contemplation is to be aware of the risk behavior. The 
model distinguishes three stages of awareness. 
What these models have in common is that they empha-
size the rationality of human behavior. They assume that 
the health behaviors to be predicted, in our case adherence, 
are considered to be the end-product of a rational decision-
making process based upon deliberate, systematic processing 
of the available information. 
Which theoretical framework to apply should be based 
on the research question, the target health behavior, and the 
specific target group. The prerequisites for choosing a model 
are therefore to have adequate knowledge on the different 
theoretical frameworks and adequate knowledge on the spe-
cific empirical literature. The researcher can also decide to 
integrate several theoretical frameworks, because the goal is 
to get optimal insight into the determinants of behavior. One 
can add some concepts to an existing model or assemble two 
frameworks together. The drawback of this method is that 
connections or processes from specific theories can become 
disconnected or misinterpreted.
We choose to use the extended HBM (Figure 1) as a 
guide to explore and explain the numerous possible determi-
nants of adherence, because it fits the possible determinants 
of adherence that we found the best (see Table 1, which is 
explained below). The HBM asserts that the decision to 
engage in preventive health behaviors, such as adherence, 
is influenced by four perceptions: the perceived severity of 
an illness, the perceived susceptibility of the individual to 
that illness, the perceived benefits associated with a health 
behavior to address the illness, and the perceived barriers 
to engage in the health behavior. The weighing of pros and 
cons of performing the health behavior was mentioned 
repeatedly in the focus group interviews as an important 
step toward taking the medication. This is also one of the 
key features of the HBM. The model focuses on severity, 
susceptibility, and perceived utility of the regimen (efficacy 
and the abundance of benefits over costs). These belief 
components have been found to affect intentions to adhere 
to various health-related behaviors.16 The model is thus in 
line with our findings from the literature review and the 
patient interviews. 
Another reason for choosing the HBM is that it has been 
used widely in the prediction of adherence behavior15 and 
has a larger level of evidence for the prediction of adherence 
than other theoretical frameworks. 
Figure 1 extended health Belief Model.
Individual perceptions Modifying factors Likelihood of action
Perceived severity
Demographics
Psychological characteristics
Perceived threat
Perceived benefits versus
perceived barriers
Perceived self-efficacy
Action
Nonadherence to
pharmaceutical treatment
Cues to action (adherence)
Perceived susceptibility
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Selection of questions 
In deterministic research, one can distinguish between proxi-
mal, distal, and ultimate determinants. Proximal determinants 
are closely related to adherence and are usually modifiable; 
distal determinants influence adherence behavior indirectly; 
and ultimate determinants are even further away from the 
actual behavior but have an indirect influence on behavior 
through intermediate processes.22 Distal and ultimate deter-
minants are mostly unmodifiable. In Table 1, factors that 
are thought to influence adherence behavior are clustered 
according to the HBM and ordered hierarchically from 
distal to proximal determinants. For example, the factor 
“race other than white”, which was found in the systematic 
literature review, is a demographic factor and distal. It is 
also unmodifiable. 
It seems logical that only proximal factors will be 
included in our sample. However, we also chose to include 
some distal factors in our questionnaire, because we want to 
gain insight into the intermediate pathways in which distal 
determinants can influence adherence. Once we gain insight 
into all distal and proximal determinants, we can create tai-
lored interventions for special target groups. 
The underlined factors shown in Table 1 were the base 
of the constructs we used to develop our questionnaire. We 
searched in the scientific literature for validated questionnaires 
that measure the constructs from Table 1. The questionnaires 
that we extracted questions from were the short version Pain 
Anxiety Symptoms Scale,23  Arthritis Helplessness Index,24 the 
Revised Illness Perception Questionnaire,25 the Coping with 
Rheumatic Stressors Questionnaire,26 Pijn  Coping  Cognitie 
Lijst (Pain Coping and Cognition Scale),27 the Ways of 
Coping Questionnaire,28 the Multidimensional Health 
Locus of Control Scale,29 the Chronic Pain Acceptance 
Questionnaire,30 and the Nederlandse persoonlijkheids-
vragenlijst (Dutch Personality Questionnaire).31 We studied 
the main articles on these questionnaires for the factor struc-
ture of the questionnaires and chose per factor the questions 
with the highest factor loading. We assumed that anxiety, 
depression, self-efficacy, and beliefs about medication might 
have a high impact on adherence behavior. Therefore, we 
used the complete scales to measure this construct. These 
scales are described in detail below.
Beliefs about Medicines Questionnaire
Patient beliefs about medicines were assessed using the 
Beliefs about Medicines Questionnaire (BMQ), which has 
been validated for use in patients with somatic chronic 
illnesses.32 The BMQ measures patient beliefs about the 
necessity of a prescribed medication to control their illness, 
and their concerns about the potential adverse consequences 
of taking the medication. Beliefs about necessity and con-
cerns are both measured with five items rated on a five-point 
Likert scale. The total scores of the Necessity and Concerns 
scales range from 5 to 25, with higher scores indicating stron-
ger beliefs. Among general medical patients, the subscales 
have reported Cronbach’s alpha of 0.86 for the Necessity 
scale to 0.51 for the Concerns scale. 
hospital Anxiety and depression Scale
Anxiety and depression were measured with the Dutch version 
of the Hospital Anxiety and Depression Scale (HADS),33 screen-
ing anxiety and depression symptoms in a hospital setting on 
two subscales. The HADS consists of 14 items; seven items 
measuring anxiety and seven items measuring depression. Each 
item presents a statement, and patients are asked to respond to 
these items on a four-point Likert scale ranging from 1 (do not 
agree at all) to 4 (agree very much). 
Medication Understanding and Use Self-efficacy Scale
The Medication Understanding and Use Self-efficacy 
(MUSE) questionnaire is a research tool that can be used 
in clinical and research settings to assess patients’ under-
standing and use of prescription medication. The MUSE 
questionnaire consists of two scales: “learning about medi-
cation,” with Cronbach’s alpha of 0.68, and “taking medi-
cation” with Cronbach’s alpha of 0.77.34 Taken together, 
the two factors account for 55% of the total variance of 
understanding medication instructions. MUSE scores are 
continuous and can range from 0 to 10, with low scores 
indicating patients’ low understanding of prescription 
medication use. 
The final item pool consists of 217 items. Besides the 
constructs described before, the questionnaire also covers 
demographic questions such as sex, age, education, work, 
and social situation. The final item pool was tested by ten 
individual established RA patients. These patients were asked 
if they found some questions difficult to understand or dif-
ficult to answer. They were also asked what they thought of 
the length of the questionnaire. Following their responses, 
some questions were adapted. 
Methods to measure adherence 
Methods to measure adherence are described by de Klerk 
(2001).35 There are many methods, with their own advan-
tages and disadvantages. Measurement instruments can be 
divided in direct measurement methods, which prove that 
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the drug reached the site of action, and indirect measure-
ment methods, where there is no proof of ingestion. An ideal 
measurement instrument should be: 1) valid, 2) reliable and 
sensitive to change, and 3) feasible: the patient should not 
be aware of compliance measurement, the method should 
not be invasive, and the researcher/physician should always 
have access to the data. However, an adherence measure-
ment instrument that possesses all these features does not 
exist. Therefore, when choosing a measurement method, 
de Klerk suggests to pay attention to: 1) the objective of 
measuring adherence, 2) the desired level of precision of the 
instrument, 3) the need to prove ingestion of the medication, 
and 4) whether or not the patient has to be unaware of the 
adherence measurement. 
The objective of measuring adherence in our study is to 
ensure that the drug is approximately ingested as prescribed. 
The desired level of precision of the instrument needs to be 
high. Although timing adherence is not relevant when using 
DMARDs, patients in this study will use different DMARDs 
with different regimens. Since we also need to look for 
variations in adherence between different DMARDs, we 
need a precise measurement instrument. Ideally, we want the 
patients to be unaware of the adherence measurement, but 
since we are ethically obliged to inform patients about the 
scope of the study, this is not entirely possible. From daily 
practice, it is however known that patients easily forget that 
they are being monitored and that electronic monitoring does 
not interfere with adherence behavior.36 
We therefore chose as a primary measurement instrument 
the electronic monitoring with medication event monitoring 
systems (MEMS). It is noninvasive and gives stable results. 
It is also one of the best indirect methods.3 The MEMS uses 
a microprocessor in the medication container cap to record 
the day and time of each vial opening. Electronic moni-
toring offers the advantage of assessing adherence over a 
continuum. This method has proven to be superior to patient 
self-reports and pill counts in the measurement of adherence 
in studies of adults requiring chronic medication.37,38 The only 
drawbacks of using MEMS is that it is relatively expensive 
and that it does not prove ingestion of the medication. The 
primary outcome measure of our study is the adherence rate 
to oral DMARDs in the first 3 months of disease measured 
with MEMS. The MEMS adherence rate will be calculated by 
dividing medication events or bottle openings by doses pre-
scribed for the interval. The adherence rate varies between 0 
(complete nonadherence) and 100 (complete adherence). 
Because it is recommended to use multiple measurement 
methods of adherence to increase reliability,3 we also chose to 
use questionnaires for the measurement of adherence. Patient 
questionnaires do not give detailed overviews on the time of 
ingestion, but they are a cheap way to measure adherence. 
When a patient needs to start using DMARDs subcutane-
ously, we cannot use MEMS anymore, but we can still use 
the questionnaires for adherence measurement. 
The Compliance Questionnaire Rheumatology (CQR) is 
a self-report measure consisting of 19 statements related to 
compliance. Patients are asked to respond to these items on a 
four-point Likert scale ranging from 1 (do not agree at all) to 4 
(agree very much). The total score is a continuous variable 
ranging from 0 (complete noncompliance) to 100 (perfect 
compliance). The CQR has been validated in patients with 
inflammatory rheumatic diseases, against an MEMS. The 
19-item CQR compared well with electronic monitoring 
over 6 months with a sensitivity of 98%, specificity of 67%, 
and an estimated kappa of 0.78, to detect nonadherence.39 As 
the CQR does not measure adherence directly, but relies 
partly on behavioral items, the use of the CQR could teach 
us more about the correlation between specific cognitions 
and adherence behavior. 
We also chose a direct physical method to measure adher-
ence: concentration measurement. The advantage of this method 
is that it proves ingestion of the medication. The drawback of 
concentration measurements is that at the time of measurement, 
you only measure drug concentrations from medication which 
has been ingested the previous day. So if a patient has taken 
their medicine the day before, the method will report a perfectly 
adherent patient. This method is mostly used intermittently, 
but if you want to retrieve full adherence data, ideally you will 
have to do concentration measurements every day, which is, of 
course, invasive and therefore difficult to employ.
For RA patients, it would be interesting to measure levels 
of DMARDs. RA is commonly treated with one or more 
DMARD, of which methotrexate (MTX) is the first drug 
of choice. MTX needs to be ingested weekly, and it takes 
6 to 8 weeks to have an effect on the arthritis symptoms.40 
We expect that this drug will be prescribed to approximately 
95% of our study sample. Measurement of MTX serum con-
centration is not possible, since this is cleared rapidly.41 How-
ever, MTX accumulates intracellularly into polyglutamates 
(PGs) when ingested. This process takes approximately 
6 months. Longer retained intracellular red blood cell MTX 
concentrations might be a good indicator for adherence. 
Incorporating these PG measurements in normal clinical 
practice is relatively easy, as it is normal practice to draw 
blood from rheumatology patients on a regular basis, and 
that blood can also be used for the MTX PG measurement. 
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Blood samples will be drawn, and intracellular MTX will be 
measured and compared to MEMS adherence data. Patients 
will be classified as nonadherent, partially adherent, and 
adherent. Nonadherence will be defined as MTX PG levels 
below the analytical detection limit. 
Clinical outcome
In adherence studies, it is recommended to take clinical out-
comes into account. While clinical outcomes cannot stand 
alone as an adherence measure, they can tell us something 
about the relationship between the adherence percentage and 
clinical outcome. Especially when you want to dichotomize 
an adherence percentage into “adherent” and “nonadher-
ent”, measures of clinical outcome can be helpful to find a 
clinically relevant cut-off point. We use the Disease Activity 
Score 28 (DAS28)42 and the Health Assessment Question-
naire (HAQ)43 to measure clinical outcome of disease. These 
measures are described below. 
dAS28
To evaluate disease activity, the DAS28 is calculated every 
3 months. The DAS28 is a composite score of erythrocyte 
sedimentation rate and the number of tender and swollen 
joints as per the 28-joint count as well as a patient global 
assessment. 
hAQ
Physical functioning was measured using the validated Dutch 
version of the consensus HAQ.43 This self-administered ques-
tionnaire is a validated measure of disability which includes 
20 specific functions that are grouped into categories: dress-
ing and grooming, arising, eating, walking, personal hygiene, 
reaching, gripping, and other activities. The average of these 
scores represents a physical functioning score. HAQ scores 
range from 0 (no difficulty) to 3 (unable to do). The HAQ has 
been found to have good criterion validity (correlations between 
questionnaire or interview scores and task performance 0.71–
0.95) as well as test-retest reliability (correlations 0.87–0.99). 
Study design
ethics statement
This study was approved by the Medical Ethics Committee. 
Written informed consent will be obtained before the start 
of the study. When giving informed consent, patients state 
that they are aware that their data will be used for research 
purposes and that the data will be anonymized. 
Determinants of adherence in the first 3 months of 
DMARD use are studied in a cohort study with 1 year 
 follow-up, which will take place in the rheumatology outpa-
tient clinic of the hospital where the patient is treated. The 
study will be performed in eleven different rheumatology 
outpatient clinics of eleven participating hospitals. Adult 
patients who are diagnosed with RA (according to the new 
or old American College of Rheumatology criteria for RA), 
psoriatic arthritis, or undifferentiated arthritis and are pre-
scribed oral DMARDs will be invited by their rheumatologist 
to participate in the study. Data will be collected at five time 
points by one of the research nurses or specialized rheumatol-
ogy nurses in the outpatient clinic where the patient is treated. 
T0 is the baseline measurement, performed within 2 weeks 
after the prescription for DMARDs. T1 will be performed 
3 months after T0, T2 at 6 months, T3 at 9 months, and T4 at 
12 months after start of medication. This study has been 
approved by the Medical Ethics Committee and all medical 
boards of the participating hospitals gave their consent for 
participation in the study. 
Participants are asked to fill in the item pool at baseline 
(T0) and at the 6 month follow-up (T2). Every 3 months, 
physical functioning is measured, and patients are asked to fill 
in an adherence self-report measure. In Table 2, a schematic 
overview of measures is presented. 
Study population
Inclusion criteria for participation in the study are: being newly 
diagnosed with RA, psoriatic arthritis, or  undifferentiated 
arthritis; being prescribed a DMARD or prednisone for the 
first time; aged above 18 years; and being able to take their 
medication without the assistance of others. Reasons for 
Table 2 Flowchart of measures during follow up
Measure T0 T1 T2 T3 T4
Adherence
MeMS Continuous
CQR X X X X X
MtX polyglutamates X X X X
Clinical outcome
dAS28 X X X X X
hAQ X X X X X
Factors associated with adherence
BMQ X X
MUSe X X
hAdS X X
Item pool X X
Note: X, measured at the time point indicated in the column heading.
Abbreviations: BMQ, Beliefs about Medicines Questionnaire; CQR, Compliance 
Questionnaire Rheumatology; dAS28, disease Activity Score 28; hAdS, hospital 
Anxiety and depression Scale; hAQ, health Assessment Questionnaire; MeMS, 
medication event monitoring systems; MtX, methotrexate; MUSe, Medication 
Understanding and Use Self-efficacy scale; T0, baseline; T1, 3 months after T0; T2, 
6 months after t0; t3, 9 months after t0; t4, 12 months after t0.
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exclusion are illiteracy and the inability to use the MEMS. 
Patients with cognitive impairments, visual impairments, and 
serious addictions were excluded from participation in the 
study, because they are mostly not able to take their medica-
tion without the assistance of others. The inclusion of patients 
started January 2012 and ended in December 2013. The 1-year 
follow-up of all patients will be finished by January 2015.
Construction of prediction rule
We strive to include 300 early polyarthritis patients, so that 
we have enough cases to include approximately nine predic-
tive factors for adherence in the prediction rule.39,44
The amount of items will be reduced stepwise. First, items 
are reduced based on the frequency distribution of answer 
categories. Second, an exploratory factor analysis will be 
performed. The minimum amount of questions allowed per 
factor is five. Third, per factor, items will be reduced with 
item response theory. Only those questions will be included 
that distinguish the most within the latent factor. 
Having reduced the items, a multivariate logistic regres-
sion with backward selection will be performed. After hav-
ing fitted the significant factors in the model, we prevent 
the model from overfitting using a shrinkage method.45,46 
Discussion
This article describes how to develop a tool for the prediction 
of adherence for patients with a chronic disease. It describes 
the various steps to be taken for the development of our 
tool for the prediction of adherence to DMARDs for early 
arthritis patients. 
The stepwise procedure that we describe is thorough, but 
there are some pitfalls to take into account. First, the choice 
for a theoretical framework can be arbitrary. Although we do 
feel that the HBM fits our determinants the best, a different 
framework could have been applied as well. We focused 
on factors such as social norm and communication with the 
health care provider, and thus chose the HBM. If we had 
chosen a different framework, for example the Transtheoreti-
cal Stages of Change model, the focus of our study would 
have been on intrinsic factors. Using a theoretical framework 
for the prediction of adherence has many advantages, but 
it has one major drawback. A social cognition model can 
only be used to predict conscious and motivated behavior. 
Unconscious nonadherence, for example through simply 
forgetting to take the medication, cannot be predicted with 
a social cognition model.
Second, the selection of questions from validated ques-
tionnaires depended on what was available in the literature. 
This set of questions might therefore not be complete. We 
also had to make some choices concerning the questionnaires. 
There are for example many questionnaires available on 
coping, all based on slightly different theories. We chose to 
use questions from a general coping questionnaire as well 
as items from specific coping with chronic pain, and coping 
with arthritis questionnaires. We chose these questionnaires 
because these were most often used in research. 
The outcome measure of our study is adherence. Previ-
ous literature has shown that adherence outcomes strongly 
depend on the measurement instrument chosen. We gave 
an overview of the different methods to measure adherence 
and pointed out the issues around choosing the right method. 
Because there is no “gold standard” to measure adherence, 
we will use in our example three different methods, both 
direct and indirect, to assess adherence behavior. Within 
the measurement of MTX PGs we can differentiate between 
nonresponse to MTX treatment and nonadherence or partial 
adherence to MTX treatment. We can correlate these mea-
surements with the indirect adherence measurements with the 
MEMS, and by that means validate the MTX polyglutamate 
measure. When validated, this is the first direct measure for 
adherence to MTX treatment. It is also a relatively cheap 
method which is easy to implement in daily practice. 
The item pool that we constructed is ready to be used 
in the study. In this phase, we can encounter some pitfalls. 
First, the patient may find the item pool too long and may 
find that items are similar. This may cause patients to become 
unmotivated to be followed up in the study. It is therefore 
important to try to reduce the number of questions in the 
item pool and to explain to patients that they are not filling 
out an end-stage questionnaire, but an item pool that has to 
become a questionnaire. We also expect that our cohort is 
vulnerable to selection bias. Those patients who do not adhere 
to their therapy are less likely to participate in the study, or 
are likely to become lost to follow-up. When setting up a 
cohort study for the measurement of medication adherence, 
researchers should be aware of these pitfalls and also try 
to gather information about patients who are not willing to 
participate or who are lost to follow-up. 
In this article we described the steps to be taken for the 
development of a questionnaire for the prediction of adherence 
in patients with a chronic disease. We discussed for every step 
the different options and pitfalls. We concluded each section 
with the choices that we made regarding these steps. 
Disclosure
The authors declare no conflicts of interest in this work.
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